The analysis of the IPF-ARGs-TF-miRNA-drug network highlighted three endothelin receptor antagonists targeting EDNRB: Bosentan, Sitaxentan, and Ambrisentan. Here, TF is linked to idiopathic pulmonary fibrosis.